VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Subcutaneous epcoritamab in R/R B-cell non-Hodgkin lymphoma

Martin Hutchings, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, discusses the results from a Phase I/II dose-escalation study investigating subcutaneous epcoritamab (CD3xCD20) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Additionally, Dr Hutchings outlines safety signals detected during the clinical trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter